April 16, 2026: ‘s-Hertogenbosch, the NetherlandsPamDx, an innovative CRO in biomarker research and in-vitro diagnostic services, today announced the successful closing of a €13 million Series A financing round. The...Read More
We hope to inspire you at the 2026 AACR Annual Meeting in San Diego, where 7 cutting-edge scientific posters from PamGene and our collaborators will highlight how our functional kinase...Read More
At the AACR Annual Meeting 2025, PamGene presented six scientific posters showcasing how our kinase activity profiling technology accelerates drug discovery and enhances understanding of cancer biology. These studies demonstrate...Read More
‘s-Hertogenbosch, the Netherlands, March 21, 2024 – PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, announced today the presentations of seven posters from...Read More
‘s-Hertogenbosch, The Netherlands, June 27, 2023 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing a blood-based cancer immunotherapy guidance test called IOpener®, is one of the 51...Read More
PamGene, together with collaborators, presented insightful Applications of our kinase activity profiling technology through Posters and at our Booth # 75Read More
‘s-Hertogenbosch, the Netherlands; Lausanne, Switzerland – January 17, 2023 MAINLINE, a Dutch-Swiss consortium between PamGene International B.V., Alithea Genomics SA and Lausanne University Hospital (CHUV), has been awarded a Eurostars...Read More
‘s-Hertogenbosch, the Netherlands, December 1, 2022 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, will present the results of its IOpener®-NSCLC test on...Read More
‘s-Hertogenbosch, the Netherlands, July 21, 2022 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, today announced its IOpener®-NSCLC test has been registered as...Read More
‘s-Hertogenbosch, the Netherlands, July 5th, 2022 PamGene International B.V., an in-vitro diagnostics and biomarker services company developing blood-based immunotherapy guidance tests, today announced its IOpener®-melanoma test has been registered as...Read More
